Sanofi-aventis and Kyowa Hakko Kirin enter anti-LIGHT fully human monoclonal antibody agreement

Published: 10-Jun-2009
Sustainability Research & Development

Sanofi-aventis and Kyowa Hakko Kirin have signed a licensing agreement under which sanofi-aventis has received worldwide rights to Kyowa Hakko Kirin\'s anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes) human monoclonal antibody.


Sanofi-aventis and Kyowa Hakko Kirin have signed a licensing agreement under which sanofi-aventis has received worldwide rights to Kyowa Hakko Kirin's anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes) human monoclonal antibody.

This antibody is at preclinical stage and will be used in the treatment of ulcerative colitis and Crohn's disease. The development could also be pursued in further indications such as rheumatoid arthritis.

"We are very pleased with this new agreement with Kyowa Hakko Kirin that will strengthen sanofi-aventis" pipeline in the field of inflammation," said Marc Cluzel, senior vice president of r&d at sanofi-aventis. "There are very important breakthroughs in the field of inflammation such as anti-TNFs but unfortunately not all patients benefit from these new therapies. Anti-LIGHT antibody may represent an alternative therapy for those patients."

Sanofi-aventis has exclusive rights to develop the product worldwide, except in Japan and Asian countries where both parties will co-develop the product.

Kyowa Hakko Kirin's upfront and milestone payments could reach US$315m.

The La Jolla Institute of Allergy and Immunology (LIAI) discovered the LIGHT molecule. Kyowa Hakko Kirin California, a subsidiary of Kyowa Hakko Kirin, and LIAI developed the anti-LIGHT human monoclonal antibody.

  • Companies:
  • Sanofi
See more

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

Read more
The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)

Trending Articles

  1. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  2. Olon releases its annual ESG report The Italian Group, leading international API supplier, presents the 2023 sustainability report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates
  3. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  4. CDMO market trends and dynamics The rise of the embedded model

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)
Research & Development

Sanofi's tolebrutinib meets primary endpoints in Phase III HERCULES MS trial

The therapeutic has the ability to delay the onset of confirmed disability progression in patients, which is significant area of unmet need in the MS patient population
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Packaging

Haleon and Sanofi to explore sustainable packaging alternatives

The Bottle Collective’s mission is to industrialise a recyclable high-speed, low-cost dry moulded fibre bottle process
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Subscribe now